Tag:
GlaxoSmithKline
Latest Headlines
Latest Headlines
Don't split up the dynamic duo of GSK's vaccines and drugs, vax chief says
Prominent U.K. investor Neil Woodford has been calling for a four-way breakup of GlaxoSmithKline, a company he says is too "complicated" for its own good. But take it from GSK vaccines chief Moncef Slaoui--splitting apart is a bad idea, at least on the vaccines front.
GSK chief Witty opens up to spinoff talk, with consumer health an obvious choice
GlaxoSmithKline CEO Andrew Witty may be coming around on a breakup. At the J.P. Morgan Healthcare Conference, Witty said he's open to the idea and pegged his consumer health joint venture with Novartis as a possible option.
#JPM16 Roundup: What you need to know on Pfizer, Sanofi and more
SAN FRANCISCO-- On Monday, we brought you the lowdown from the J.P. Morgan Healthcare Conference, with company presentations from pharma giants including Novartis and Merck & Co. Today, we're back with our latest roundup, big names and not-so-big.
Deal in Russia could cause Pfizer, GSK to lose contracts
A unit of Rostec, Russia's state corporation, has inked a pact with the Serum Institute of India to locally produce several vaccines in Russia, the Pharma Letter reports, a development that could bring about "significant losses" for Pfizer and GlaxoSmithKline in the country.
GSK's Slaoui sees 'major' vaccine market disruption for Merck as shingles candidate progresses
SAN FRANCISCO-- Look out, Merck & Co.: GlaxoSmithKline expects its shingles candidate, Shingrix, to be a "major market disrupter" when it wins approval.
Nearly a year into Novartis integration, GSK CEO won't discount vaccines spinoff
Since the completion of its massive asset swap with Novartis, GlaxoSmithKline has been working to integrate the Swiss drugmaker's vaccines stall into its own operations. Now, at the J.P. Morgan Healthcare Conference, GSK CEO Andrew Witty cited "optionality" for the unit in the future, saying the drugmaker wouldn't discount a future spinoff.
GlaxoSmithKline and Five Prime ditch lung cancer ambitions as rivals pile in
Partners GlaxoSmithKline and Five Prime Therapeutics are abandoning their hopes of developing an early-stage drug for lung cancer, pivoting to mesothelioma as the landscape gets more and more competitive.
Advair copycat queue gets crowded with PhIII data on Vectura prospect
On Friday, Vectura said it had wrapped up clinical trials for an Advair generic dubbed VR315, which could take on GSK's respiratory behemoth in early 2018. Now, the company will "look forward to submission of the file, positioning VR315 competitively in what will be a major value opportunity," Vectura chief James Ward-Lilley said in a statement.
Will GSK's no-speaker-fee system work? Execs say yes; critics, not so much
GlaxoSmithKline has taken some bold steps to polish its image, tarnished by a Chinese bribery scandal and $3 billion settlement with the U.S. government. But naysayers blame its first big moves--nixing sales-rep quotas and pegging bonuses to "softer" measures instead--for disappointing roll-outs for several new meds.
GSK whistleblower claims to have been fired after emailing CEO about Nicoderm concerns
GlaxoSmithKline's Nicoderm products are among the leaders in helping smokers kick their habits. But a former employee says the study that showed their edge over competitors was flawed and that he got the boot for pointing it out to his bosses and giving a heads-up by email to CEO Andrew Witty.
